Economic Evaluation of Stream™ Platform (CostAL)

Economic Evaluation of Stream™ Platform for the Early Detection of Anastomotic Leakage After Gastrointestinal Surgery

This Economic Evaluation study is a multi-center, two-arm, non-randomized, interventional trial. The purpose of this study is to evaluate the economic and patient outcomes of using the Stream™ Platform for early detection of anastomotic leakage after gastrointestinal surgery. The trial will track patient outcomes and healthcare costs in two groups: the intervention group, where the Stream platform is deployed, and the control group, before the integration of the Stream™ Platform. The data collected from both groups will be compared to assess the impact of implementing the Stream™ Platform and early leak detection on overall patient outcomes and healthcare costs.This trial will include hepatobiliary, colorectal, and trauma/acute care patient populations.

Study Overview

• Status: Recruiting
• Conditions: Anastomotic Leak
• Intervention / Treatment: Device: Stream™ Platform; Device: Stream™ Platform with Risk Score Omitted

• Study Type: Interventional
• Enrollment (Estimated): 215
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Dr. Pablo E Serrano, MD, MPH, FACS; Phone Number: 43872 (905) 521-2100; Email: serrano@mcmaster.ca

Study Locations

• Canada
  • Ontario
    • Hamilton, Ontario, Canada, L8L 2X2
      • Not yet recruiting
      • Hamilton General Hospital - Hamilton Health Sciences
      • Contact: Dr. Edward Passos, MD, FRCSC; Phone Number: 44237 905-521-2100; Email: passosem@mcmaster.ca
  • Ontrario
    • Hamilton, Ontrario, Canada, L8V 1C3
      • Recruiting
      • Juravinski Hospital- Hamilton Health Sciences
      • Contact: Dr. Pablo E Serrano, MD, MPH, FACS; Phone Number: 43872 (905) 521-2100; Email: serrano@mcmaster.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 18 years - Male or Female
• Subject understands and has voluntarily signed and dated the informed consent form (ICF).
• Subjects must be willing to comply with trial requirements
• Subject has performed an open or laparoscopic surgery with peritoneal or pelvic drainage

Exclusion Criteria:

• Subject is pregnant
• Subject will be discharged < 8 hours post-surgery
• 24 or more have passed since the end of the subject's surgery
• Involvement in the planning and conduct of the clinical investigation
• Subject is allergic to contrast medium
• Participation in another investigational drug or device study which would interfere with the endpoints of this study
• Device does not attach to drain used on the subject

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention Group; Stream™ Platform will be attached to the abdominal/pelvic drains of the patients enrolled in this group. The platform will conduct continuous pH and electrical conductivity measurements of the abdominal drain fluid. The continuous pH and electrical conductivity measurements will be used to calculate a Risk Score that will be provided to surgeons. Surgeons will employ the Risk Score produced alongside the standard of care for guiding the postoperative care of patients.	Device: Stream™ Platform; Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor). Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage.
Sham Comparator: Control Group; Stream™ Platform will be attached to the abdominal/pelvic drains of the patients enrolled in this group. The platform will conduct continuous pH and electrical conductivity measurements of the abdominal drain fluid. However, Stream™ Platform will not generate a Risk Score and therefore, will not impact the postoperative care of patients. All procedures will be conducted as per the standard of care or institutional policies. Stream™ Platform will only be used for observation in the Control group.	Device: Stream™ Platform with Risk Score Omitted; Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor). This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform.; Other Names: NERv's Inline Device

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Does Stream™ Platform integrate well with the existing clinical workflow (1)?	Quantify average time spent by clinical research coordinator (CRC)/delegate interacting with Stream™ Platform (during attachment, daily calibration, and detachment) in minutes	Through study completion, an average of 1 year
Does Stream™ Platform integrate well with the existing clinical workflow (2)?	Observe overall compliance to Instructions for use though quantification of the number of daily calibrations completed	Through study completion, an average of 1 year
Does Stream™ Platform integrate well with the existing clinical workflow (3)?	Quantify the overall reported satisfaction score of the CRC/delegate through surveys.	Through study completion, an average of 1 year
Does Stream™ Platform reduce the cost of care for anastomotic leak patients in colorectal, hepatobiliary, and trauma and acute care surgeries (1)?	Quantify the average number of tests and procedures performed to detect anastomotic leakage before and after the implementation of Stream™ Platform.	Upon study completion (12 months)
Does Stream™ Platform reduce the cost of care for anastomotic leak patients in colorectal, hepatobiliary, and trauma and acute care surgeries (2)?	Quantify the average patient cost/cost of hospitalization and by-department cost (log of all billed items including medications, laboratory investigations, diagnostic/radiology investigations, hospital length of stay, ICU admission, re-admission within 30 days after discharge, time of discharge and therapeutic services) for colorectal, HPB, and trauma and acute care patients before and after the implementation of Stream™ Platform.	Upon study completion (12 months)
Number of Subjects with Device Related Adverse Events	An adverse event assessment will be performed in accordance to ISO 14155 standards to determine the number of device related adverse events.	Upon study completion (12 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Does Stream™ Platform allow for earlier postoperative anastomotic leak detection in colorectal, HPB, and trauma and acute care surgeries compared to clinical judgment/laboratory assessment (1)?	Quantify the average time to detect anastomotic leakage after colorectal, HPB, and trauma and acute care patients using conventional diagnostic techniques (PRE) and after the implementation of Stream™ Platform (POST).	Upon study completion (12 months)
Does Stream™ Platform allow for earlier postoperative anastomotic leak detection in colorectal, HPB, and trauma and acute care surgeries compared to clinical judgment/laboratory assessment (2)?	Quantify the average sensitivity, specificity, and overall accuracy of conventional diagnostic techniques for detection of anastomotic leakage after colorectal, HPB, and trauma and acute care surgeries in contrast to the average sensitivity, specificity, and overall accuracy of Stream™ Platform.	Upon study completion (12 months)
Does Stream™ Platform reduce the need for non-conservative management and hospital re-admission that is associated with anastomotic leak patients in colorectal, HPB, and trauma and acute care surgeries (1)?	a. Quantify the average rate of type of re-intervention due to anastomotic leakage after colorectal, HPB, and trauma and acute care surgeries before and after the implementation of Stream™ Platform.	Upon study completion (12 months)
Does Stream™ Platform reduce the need for non-conservative management and hospital re-admission that is associated with anastomotic leak patients in colorectal, HPB, and trauma and acute care surgeries (2)?	Quantify the average number of emergency re-admissions within 30 days after discharge due to anastomotic leakage in colorectal, HPB, and trauma and acute care surgeries before and after the implementation of Stream™ Platform.	Upon study completion (12 months)
Does Stream™ Platform reduce adverse events that are associated with anastomotic leak patients in colorectal, HPB, and trauma and acute care surgeries?	Quantify the average number of adverse events (such as rate of secondary postoperative complications, rate of permanent stoma, 30-day mortality, etc.) due to anastomotic leakage after leakage in colorectal, HPB, and trauma and acute care surgeries before and after the implementation of Stream™ Platform.	Upon study completion (12 months)

Collaborators and Investigators

• Sponsor: FluidAI Medical
• Collaborators: Hamilton Health Sciences Corporation; Ontario Bioscience Innovation Organization

Study record dates

Study Major Dates

• Study Start (Actual): December 6, 2023
• Primary Completion (Estimated): August 1, 2024
• Study Completion (Estimated): August 1, 2024

Study Registration Dates

• First Submitted: July 18, 2023
• First Submitted That Met QC Criteria: August 8, 2023
• First Posted (Actual): August 16, 2023

Study Record Updates

• Last Update Posted (Estimated): February 29, 2024
• Last Update Submitted That Met QC Criteria: February 27, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Anastomotic Leak
• Other Study ID Numbers: CLS0007

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No